CheckMate -205 Phase 2 trial

November 27, 2018

Opdivo Halts Hodgkin’s Progression in Those Who Earlier Had Achieved Remission, Study Shows

News

Re-treatment with Opdivo (nivolumab) may be a safe and effective option to halt disease progression in patients with classical Hodgkin’s lymphoma (cHL) who previously achieved disease remission with the treatment, a ... Read more

November 16, 2018

Opdivo Plus ASCT Ably Treats Classical Hodgkin’s Lymphoma Patients with Few Options, Study Says

News

Classical Hodgkin’s lymphoma patients who failed to respond to autologous stem cell transplant (patient-derived cells) showed “unprecedented” low relapse rates after being given Opdivo (nivolumab) followed by an allogeneic, or donor-derived, ... Read more

November 29, 2016November 29, 2016

Opdivo Approved in EU for Certain Advanced Classical Hodgkin’s Lymphoma Patients

News

The European Commission has approved the immunotherapy agent Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical Hodgkin’s lymphoma (cHL) following autologous stem cell transplant (ASCT) ... Read more